SCHEDULE: Deep Track Capital Amends Oruka Therapeutics Stake

Deep Track Capital and affiliated entities disclose an updated beneficial ownership of Oruka Therapeutics, Inc. common stock, collectively holding approximately 8.93%.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., David Kroin, and Deep Track Special Opportunities Fund, LP. (collectively, "Deep Track") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Oruka Therapeutics, Inc.
• As of December 31, 2025, the Deep Track entities collectively beneficially own 4,323,020 shares of Oruka Therapeutics, Inc. common stock.
• This aggregate ownership represents approximately 8.93% of the issuer's outstanding common stock, based on 48,409,232 shares outstanding as of October 31, 2025.
• Individually, Deep Track Capital, LP and David Kroin each report beneficial ownership of 2,161,510 shares, representing 4.47% of the class.
• Deep Track Biotechnology Master Fund, Ltd. reports beneficial ownership of 1,899,455 shares, representing 3.92% of the class.
• Deep Track Special Opportunities Fund, LP. reports beneficial ownership of 262,055 shares, representing 0.54% of the class.
• The filing indicates that the securities were not acquired or held for the purpose of changing or influencing control of Oruka Therapeutics, Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a specialized biotechnology investment group maintains a significant, albeit passive, stake in Oruka Therapeutics, indicating continued confidence in the company's prospects.

Positives

• A significant institutional investor group, Deep Track Capital, maintains a substantial stake (8.93%) in Oruka Therapeutics, Inc., which can signal confidence in the company's long-term prospects.
• The filing explicitly states that the securities were not acquired or held for the purpose of changing or influencing control, suggesting a passive investment strategy.

Negatives

• The individual beneficial ownership percentages for Deep Track Capital, LP and David Kroin (4.47%) are below the 5% threshold, which could indicate a reduction in their individual stakes from a previous filing, though the group's overall stake remains significant.

Risks

• While the filing states no intent to influence control, a large institutional holding (8.93% for the group) could still exert influence on corporate decisions, potentially aligning with or diverging from other shareholder interests.
• Changes in the investment strategy of a significant shareholder group could lead to large block trades, potentially impacting stock price volatility.

Future Outlook

This filing does not contain forward-looking statements or guidance from Oruka Therapeutics, Inc. It is a disclosure of beneficial ownership by an external investment group.

Industry Context

StockSavvy.ai notes that the continued significant stake by Deep Track Capital, a specialized biotechnology investor, suggests ongoing interest in the biotechnology sector and Oruka Therapeutics' specific pipeline or market position. Such institutional backing can be a positive signal in the often volatile biotech industry, indicating a belief in the company's long-term value proposition.

Comparison to Industry Standards

• This filing is a standard disclosure of beneficial ownership by an institutional investor group.
• StockSavvy.ai observes that an 8.93% stake by a specialized fund like Deep Track Capital is a substantial position, comparable to significant institutional holdings seen in other emerging biotechnology companies.
• For instance, funds like ARK Invest or BlackRock often take similar or larger positions in companies they believe have strong growth potential within their respective sectors.
• The passive nature of the investment, as stated, aligns with typical institutional portfolio management rather than activist investing.

Stakeholder Impact

• Shareholders: The continued significant ownership by a specialized institutional investor group may provide a level of confidence and stability, potentially reducing perceived investment risk.
• Management: The passive nature of the investment, as stated, suggests Deep Track Capital is not seeking to influence management decisions, allowing current management to pursue its strategic objectives without immediate activist pressure.

Key Dates

Recommendation

The filing indicates a significant, passive institutional stake by Deep Track Capital and its affiliates, collectively holding 8.93% of Oruka Therapeutics. While this signals confidence from a specialized investor, the filing itself is a routine ownership disclosure and does not provide new operational or financial performance data. The individual percentages for some reporting persons are below 5%, which could imply a reduction in their individual stakes, but the group's overall position remains substantial. Without additional information on the company's fundamentals or recent performance, a "hold" recommendation is appropriate, acknowledging the institutional backing while awaiting further operational updates.

Keywords

Oruka Therapeutics, Deep Track Capital, Schedule 13G, beneficial ownership, institutional investor, common stock, biotechnology, investment adviser, passive investment